Measuring the inflammatory response in viral infections with an eye towards MIS-C
DOI:
https://doi.org/10.46570/utjms-2026-1330Keywords:
URI, MIS-C, Inflammation, COVID-19Abstract
Multisystem Inflammatory Syndrome in Children (MIS-C) caused by a recent SARS CoV2 infection in a child, led to broad screening of acutely ill children for widespread inflammation and systemic disease due to need for early diagnosis and therapeutic intervention. This broad laboratory screening to rule-out MIS-C also inadvertently captured the patients who were found to have seasonal viral upper respiratory infections. Thus, this screening provided a unique opportunity to study the inflammatory response to some of the common viral infections. We performed a retrospective chart review for all patients under 18 who presented to the ER or were admitted to the hospital with a positive test for either 1) Viral URI, 2) Acute COVID-19, or 3) positive SARS CoV2 IgG, suggesting previous COVID-19 infection; between March 2020-October 2022. We reviewed 6628 patient encounters with 5312 encounters meeting inclusion criteria.
Here we report that patients who had COVID IgG without other infection identified, most frequently showed widespread inflammation, as indicated by 56.7% of patients with 4 or more positive MIS-C criteria suggesting a diagnosis of MIS-C. One patient had a peak of 15 positive MIS-C criteria. Several seasonal viruses showed multisystem inflammatory responses in limited patients with the most frequent occurring in adenovirus (7.6% >= 4 criteria), and peaks of 9 or 10 criteria in sporadic patients for three seasonal viruses (adenovirus, rhinovirus/enterovirus, and parainfluenza viruses). Acute SARS CoV2 demonstrated elevated inflammatory states similar to seasonal cold viruses with a limited number of patients (4.3%) with >= 4 positive criteria markers of MIS-C, and a peak of 9 criteria. The most significant and largest differences between groups were observed in COVID IgG positive patients in comparison to each of the other viral groups followed by adenovirus compared to 5 out of 6 remaining viral pathogens.
References
Kirkpatrick, G.L., The common cold. Prim Care, 1996. 23(4): p. 657-75.
McMurray, J.C., et al., Multisystem Inflammatory Syndrome in Children (MIS-C), a Post-viral Myocarditis and Systemic Vasculitis-A Critical Review of Its Pathogenesis and Treatment. Front Pediatr, 2020. 8: p. 626182.
Patel, J.M., Multisystem Inflammatory Syndrome in Children (MIS-C). Curr Allergy Asthma Rep, 2022. 22(5): p. 53-60.
Sharma, C., et al., Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison. Nat Rev Rheumatol, 2021. 17(12): p. 731-748.
Wessels, P.A. and M.A. Bingler, A comparison of Kawasaki Disease and multisystem inflammatory syndrome in children. Prog Pediatr Cardiol, 2022. 65: p. 101516.
Lin, J., et al., Emerging Insights Into the Pathophysiology of Multisystem Inflammatory Syndrome Associated With COVID-19 in Children. Can J Cardiol, 2023. 39(6): p. 793-802.
CDC, Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID—19)—CDCHAN-00432. Health Alert Network, 2020.
Henderson, L.A., et al., American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2. Arthritis Rheumatol, 2021. 73(4): p. e13-e29.
Redlberger-Fritz, M., et al., Distinct differences in clinical manifestation and viral laboratory parameters between children and adults with influenza A(H1N1)pdm09 infection--a retrospective comparative analysis. J Med Virol, 2014. 86(6): p. 1048-55.
Sik, G., et al., Mortality risk factors among critically ill children with MIS-C in PICUs: a multicenter study. Pediatr Res, 2023. 94(2): p. 730-737.
Gupta, N., et al., Viral Sepsis in Children. Front Pediatr, 2018. 6: p. 252.
Root-Bernstein, R., From Co-Infections to Autoimmune Disease via Hyperactivated Innate Immunity: COVID-19 Autoimmune Coagulopathies, Autoimmune Myocarditis and Multisystem Inflammatory Syndrome in Children. Int J Mol Sci, 2023. 24(3).
De Rose, D.U., et al., T Lymphocyte Subset Counts and Interferon-Gamma Production in Adults and Children with COVID-19: A Narrative Review. J Pers Med, 2023. 13(5).
Rodriguez-Smith, J.J., et al., Inflammatory biomarkers in COVID-19-associated multisystem inflammatory syndrome in children, Kawasaki disease, and macrophage activation syndrome: a cohort study. Lancet Rheumatol, 2021. 3(8): p. E574-e584.
de Jesus, A.A., et al., Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. J Clin Invest, 2020. 130(4): p. 1669-1682.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Matthew Durst, Maria Roufaeil, Brian Fink, Sharon Thomas, Deepa Mukundan, Daniel Barnett (Author)

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

